Screener
ImmunityBio, Inc. IBRX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Due from related parties | 3 | 46 |
| Prepaid expenses and other current assets | 26,182 | 27,761 |
| Prepaid expenses – related parties | 2,071 | 769 |
| Total current assets | 452,953 | 314,875 |
| Property, plant and equipment, net | 112,785 | 114,264 |
| Goodwill and intangible assets, net | 12,885 | 13,953 |
| Long-term inventories | 18,856 | 13,508 |
| Convertible note receivable | — | 7,380 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s total current assets?
- ImmunityBio, Inc. (IBRX) reported total current assets of $452.95M in Q1 2026.
- How has ImmunityBio, Inc.'s total current assets changed year-over-year?
- ImmunityBio, Inc.'s total current assets increased by 314.9% year-over-year, from $109.16M to $452.95M.
- What is the long-term trend for ImmunityBio, Inc.'s total current assets?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total current assets has grown at a 23.0% compound annual growth rate (CAGR), from $111.71M to $314.88M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about ImmunityBio, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude